ClinicalTrials.gg
RecruitingNCT07062978Updated Jul 14, 2025

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

A Phase 3 interventional study of QL1206 and Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
278
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
15th of 57
278 · median 120
Started
2025
with 10 others
Phase 3
11 of 87
3 open now
Primary completion
2027-01
later than 24 of 32 live
Registered
74th of 87
by date

Among the 87 studies in Osteoporosis with a site in China, this one is the 15th largest by planned enrollment of the 57 interventional ones that give a count, is one of 11 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 24 of the 32 other live ones, and was the 74th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.

03

Conditions studied

  • Postmenopausal Women With Osteoporosis at High Risk of Fracture

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who agree to participate in the study and sign the form.
  • women who can walk freely, aged 50-85 years (including 50 and 85 years old).
  • Subjects whose absolute value of bone mineral density (BMD) in the lumbar or total hip area meets T values ≤ -2.5 and > -4.0.
  • Subjects who must have at least one of the following risk factors: History of previous fragility fractures (occurring after the age of 40); history of hip fractures in fathers or mothers; increased bone turnover rate during screening; low body weight ( ≤ 19 kg/m2); advanced age (aged ≥ 65 years); current smoke.
  • The duration of spontaneous amenorrhea was >2 years or >2 years after bilateral oophorectomy. If the status of bilateral oophorectomy is unknown or if the ovaries are preserved after hysterectomy, follicle stimulating hormone (FSH) levels >40mIU/mL may be used to confirm the status of postoperative menopause.

Exclusion criteria

Exclusion Criteria:

  • Bone/metabolic disease.
  • Hyperparathyroidism or hypoparathyroidism.
  • Thyroid condition: Hyperthyroidism or hypothyroidism.
  • Rheumatoid arthritis.
  • Malabsorption syndrome.
  • Renal disease - severe impairment of kidney function.
  • Vitamin D defViciency (25-hydroxyvitamin D, 25OHD \<20 ng/mL).
  • Oral or dental diseases: previous or current evidence of mandibular osteomyelitis or osteonecrosis; Acute dental or mandibular disease requiring oral surgery; Planning invasive dental surgery; Failure to recover from dental or oral surgery.
  • Previously used denosumab drugs.
  • Use of intravenous bisphosphonates, fluoride, or strontium to treat osteoporosis within the last 5 years.
  • OOral bisphosphonates (used for at least 3 years, or used for less than 3 years but more than 3 months, with the last use occurring \<1 year before the ICF).
  • Use of any of the following drugs within 6 weeks prior to screening that may affect bone metabolism.
  • History of more than two vertebral fractures.
  • Malignant tumors.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
278 participants (estimated)

Study arms

  • Experimental
    QL1206

    QL1206 Denosumab injection(60 mg)

    Drug: QL1206

  • Active comparator
    Prolia®

    Prolia® Denosumab injection(60 mg)

    Drug: Prolia®

Interventions

  • DrugQL1206

    QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

  • Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12

    Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12

    Time frame: Baseline and 12 months

07

Study locations

1 of 1 sites recruiting
  • Zhejiang Provincial People's Hospital Bijie Hospital
    Guizhou, China
    Recruiting
    • Jun Zhang · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's planned 19 months is below that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 14, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07062978
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jun 27, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jul 14, 2025

Study contacts

Youjia Xu
Contact
sdfeyec@163.com
+86-0512-67783682

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QL1206

Start the discussion